Dialog Box

Loading...

PBAC Migalstat Submission

5 May 2017 at 12:00AM
Category: Fabry Australia News
      

Fabry Australia is encouraged that a new treatment option for Fabry Disease is being considered by the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia. The PBAC are considering Galafold® Migalastat for the treatment of Fabry Disease for listing as a new medicine in Australia. This treatment is an oral therapy but it will only become available for amenable patients (specific genetic mutations).

The PBAC invites consumers to participate in the online submission process, which is due by 7th June 2017.  To read more about this please Press Here

Category: Fabry Australia News
Tags: